Immusoft
Immusoft Corporation is a biotechnology company based in Seattle, Washington, specializing in autologous cell therapies for various human diseases. Founded in 2009, the company utilizes its proprietary Immune System Programming (ISP) technology to modify the DNA of a patient's immune cells, specifically B cells. This process transforms these cells into biofactories that can produce gene-encoded medicines, effectively replacing missing or defective enzymes and proteins. By reprogramming a patient’s cells, Immusoft aims to deliver biologics that can persist within the body for extended periods, providing a long-term therapeutic solution. The ISP technology was developed at the California Institute of Technology and is exclusively licensed by Immusoft, positioning the company as a pioneer in innovative treatments for rare diseases and infectious conditions.
Discovery Genomics, Inc. is an early-stage functional genomics company focused on discovering gene functions, validating drug targets, and designing therapeutic agents informed by genomic information. The company holds exclusive licenses from the University of Minnesota for two key technologies: "knock-downs" in Zebrafish using proprietary Morphant technology and the Sleeping Beauty Transposon. These technologies enable functional genomics research and drug target discovery, with potential applications in gene therapy. The Morphant "knock-downs" technique is utilized to suppress specific genes for functional studies, while the Zebrafish model offers a faster and more cost-effective approach to gene discovery compared to other vertebrate models. As of March 2016, Discovery Genomics operates as a subsidiary of Immusoft Corporation.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.